# NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

> **NCT06963034** · PHASE3 · RECRUITING · sponsor: **Neurocrine Biosciences** · enrollment: 284 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** NBI-1117568
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06963034
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-08
- **Primary completion:** 2027-10
- **Final completion:** 2027-10
- **Target enrollment:** 284 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06963034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06963034, "NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06963034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*